Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers
06 7월 2023 - 9:30PM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers using
immuno-oncology targeted novel biologics, today announced the
signing of an exclusive agreement with Applied Biomedical Science
Institute (ABSI) to license technology for human antibodies
targeting novel HER2 and HER3 Conformational Epitopes. The
goal is to develop proprietary multi-format biologics, including
bi-specific antibodies, and antibody drug conjugates (ADCs). The
HER2/HER3 binding ADC is targeted to have a high drug-to-antibody
ratio which should increase the anti-tumoral efficacy with an
enhanced bystander killing effect. Hillstream intends to combat
drug resistant cancers such as HER2-positive metastatic breast
cancer, gastric cancer, lung cancer and ovarian cancer.
The ErbB family of cell surface proteins, including ErbB2 or
HER2 (human epidermal growth factor receptor) and Erb3 or HER3, are
some of the most well-known and validated oncology drug targets.
Antibodies and biologics against HER2 starting with
HERCEPTIN® (trastuzumab) approved in 1998 for breast cancer,
and PERJETA®, KADCYLA® and PHESGO® generated $8.4 billion
in 2022 sales for Roche/Genentech. These antibodies bind to domains
II or IV of the extracellular portion of the HER2. HER2 is also one
of the most validated antigens for antibody drug conjugates (ADCs)
to treat HER2 positive cancers with two approved antibodies,
Roche/Genentech’s KADCYLA® and Daiichi Sankyo/AstraZeneca’s
ENHERTU®.
The Applied Biomedical Science Institute has developed
technology to target novel functional epitopes of the cancer
targets HER2 and HER3. The monoclonal antibodies being developed at
ABSI are distinct from the currently approved anti-HER2 antibodies.
ABSI has granted Hillstream an exclusive license agreement, and
Hillstream will have the opportunity to develop HER2 and HER3
antibodies, including multi-specific, ADC, and Quatramer-based
therapeutics utilizing portions of these antibodies.
“We look forward to this opportunity to work with Dr. Smider and
the Applied Biomedical Science Institute,” said Randy Milby, CEO of
Hillstream. “This agreement allows us to build our antibody
platform to advance our immune-oncology biologic pipeline with HER2
and HER3 with bi-specifics and ADC agents targeting highly
aggressive drug-resistant metastatic tumors, which represents a
major unmet need for patients.”
About Applied Biomedical Science InstituteThe
Applied Biomedical Science Institute (ABSI) is a 501(c)(3)
non-profit organization taking a leading role in basic research and
its rapid clinical translation by performing cutting-edge basic and
translational research. With deep expertise in antibody genetics,
biology, engineering, and discovery technologies, ABSI promotes
therapeutic and diagnostic translation through their own internal
research, collaborations, or licensing activities. ABSI also trains
early-stage researchers in biomedical research through
post-doctoral fellow and internship programs.
About Hillstream BioPharma, Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing novel
therapeutic candidates against drug-resistant and devastating
cancers. Hillstream uses Quatramer™, a proprietary tumor targeting
platform which extends duration of action and minimizes off-target
toxicity, with biologics, mRNA, peptides and other modalities in
the tumor microenvironment. Quatrabody™ conjugates
immuno-oncology targets with greater binding affinity than approved
therapies. Hillstream Quatramers with novel biologics developed
against proprietary undruggable epitopes of PD-1 and other
validated will enter the rapidly growing immuno-oncology
therapeutics market leading with HSB-1940, targeting PD-1, followed
by additional targets including PD-L1, HER-2 and TROP-2. For more
information, please visit: www.hillstreambio.com.
Forward Looking StatementsCertain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified using words such as “anticipate,” “believe,”
“forecast,” “estimated” and “intend” or other similar terms or
expressions that concern Hillstream’s expectations, strategy, plans
or intentions. These forward-looking statements are based on
Hillstream’s current expectations and actual results could differ
materially. There are several factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, clinical trials involve a lengthy and expensive process
with an uncertain outcome, and results of earlier studies and
trials may not be predictive of future trial results; our clinical
trials may be suspended or discontinued due to unexpected side
effects or other safety risks that could preclude approval of our
product candidates; risks related to business interruptions,
including the outbreak of COVID-19 coronavirus, which could
seriously harm our financial condition and increase our costs and
expenses; dependence on key personnel; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations.
Investors should read the risk factors set forth in our Form 10-K
for the year ended December 31, 2022 and our periodic reports filed
with the Securities and Exchange Commission. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as
of the date hereof, and Hillstream does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Investor Relations
Contact:Email: investorrelations@hillstreambio.com
SOURCE: Hillstream BioPharma Inc.
Hillstream BioPharma (NASDAQ:HILS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Hillstream BioPharma (NASDAQ:HILS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024